7.68
+2.81%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Shineway Pharmaceutical Group
Its shares trade on HKEX under the ticker 2877.HK. It has been listed since 2 December 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.65bn and net income of CN¥1.11bn. At that date it held total assets of CN¥12.55bn and shareholders' equity of CN¥9.39bn.
China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei. The company went IPO on 2004-12-02. Its main products include injections, soft capsules and granules. The Company’s subsidiaries include Yuan Da International Limited, Hong Zhan International Limited and Shineway Pharmaceutical Sales Company Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Dec 2004
- Employees
- 3,692
- Website
- shineway.com.hk ↗
Leadership
Pay as last reported
- Mr. Zhenjiang LiExecutive Chairman of the Board, since 2018CN¥25.6m
- Mr. Guozhi JiangVice President
- Mr. Yudong ZhangGeneral Manager - Sales and Marketing
- Mr. Bun Ching LeeFinancial Controller, Company Secretary
- Mr. Huimin LiExecutive DirectorCN¥2.1m
- Ms. Yunxia XinExecutive DirectorCN¥13.2m
- Mr. King Kuen HungDirector of Investor Relation, since 2005CN¥33,000
- Mr. Tiejun LiuVice President of Shineway Pharmaceutical Group Limited, since 2013CN¥800,000
- Mr. Wencheng ZhouNon-Executive DirectorCN¥142,000
- Mr. Shun Fai LiuIndependent Non-Executive DirectorCN¥142,000
- Ms. Guihua WangIndependent Non-Executive DirectorCN¥106,000
- Mr. Yat On YewIndependent Non-Executive DirectorCN¥142,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 79
- Environment
- 99
- Social
- 72
- Governance
- 66
- Direct emissions (scope 1)
- 80,760.44 t
- Energy emissions (scope 2)
- 38,727.16 t
- Value chain emissions (scope 3)
- 20,852.97 t
- Women in the workforce
- 51.95%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Shineway Pharmaceutical Group Ltd has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company boasts a strong portfolio of high-quality and effective traditional Chinese medicines, which have gained recognition and trust both domestically and internationally. This provides the company with a competitive edge and a robust customer base. Secondly, Shineway Pharmaceutical has a well-established distribution network, allowing it to effectively reach its target markets and serve customers in a timely manner. This infrastructure supports the company's growth and market expansion strategies. Additionally, the company has a dedicated and experienced research and development team, continuously innovating and developing new products to meet evolving customer needs. This commitment to innovation enhances its product offerings and keeps the company ahead of its competitors.
Weaknesses
- Despite its strengths, China Shineway Pharmaceutical Group Ltd also faces certain weaknesses that pose challenges to its operations. One significant weakness is the company's heavy dependence on the Chinese market. This reliance makes it vulnerable to changes in government regulations, economic conditions, and market dynamics within China. Such external factors can impact the company's revenue and profitability. Moreover, Shineway Pharmaceutical has been facing increasing competition from both domestic and international pharmaceutical companies. This intensifying competition puts pressure on the company's market share and pricing power, potentially affecting its financial performance.
Opportunities
- China Shineway Pharmaceutical Group Ltd has various opportunities to explore and capitalize on in the pharmaceutical industry. Firstly, the growing global interest in traditional Chinese medicines presents a significant opportunity for the company to expand its international presence and increase its revenue streams. By leveraging its strong brand and reputation, Shineway Pharmaceutical can strategically partner with international distributors or enter new markets to achieve sustainable growth. Furthermore, the increasing healthcare expenditure, particularly in emerging markets, creates a favorable market environment for the company to expand its customer base and enhance its market share. This can be achieved through strategic partnerships, mergers, or acquisitions with local players in target markets.
Threats
- Alongside opportunities, China Shineway Pharmaceutical Group Ltd faces various threats that may hinder its growth and profitability. One significant threat is the stringent regulations and compliance requirements imposed by regulatory authorities in different countries. Non-compliance or failure to meet these requirements can lead to the restriction of market access or even product recalls, negatively impacting the company's reputation and financial performance. Additionally, the ongoing trade disputes and geopolitical tensions between China and other countries can pose challenges to the company's international expansion efforts. These disruptions may result in market uncertainties, trade barriers, or changes in consumer sentiments towards Chinese products, affecting the company's sales and market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.